Administration of a GnRH agonist during the luteal phase frozen–thawed embryo transfer cycles: a meta-analysis

Abstract

At present, the precise role of GnRH agonists during the luteal phase remains uncertain. In the present study, a meta-analysis was used to evaluate the effect of administering a GnRH agonist to during the luteal phase in patients undergoing FET cycles. A literature review was carried out by searching the current content of MEDLINE, Embase, the Cochrane Controlled Trials Register and Ovid. We particularly focused upon implantation rate, CPR per transfer, and ongoing pregnancy rate. All of the trials analyzed involved a GnRH agonist administered during the luteal phase. Six trials involving 1137 women were included in our meta-analysis. All of the cycles analyzed exhibited significantly higher implantation rates, clinical pregnancy rates, and ongoing pregnancy rates in the group of patients administered with a GnRH agonist during the luteal phase compared with the control group that did not receive a GnRH agonist during the luteal phase. Our data, therefore, demonstrate that the administration of a GnRH agonist during the luteal phase can significantly increase clinical pregnancy and ongoing pregnancy rates in FET cycles. The implantation rates, clinical pregnancy rates, and ongoing pregnancy rates can significantly increase in the group of patients administered with a GnRH agonist in natural cycle FET.

摘要

GnRH激动剂在黄体期的确切作用目前仍未确定。本研究用荟萃分析评估经历FET周期的患者在黄体期间用GnRH激动剂的效果。通过搜索MEDLINE, Embase, 临床对照试验资料库和Ovid的相关内容进行文献综述。我们特别关注了植入率, 每次转移的CPR和持续妊娠率。所有分析的试验均涉及在黄体期用GnRH激动剂。荟萃分析纳入了6项涉及1137名女性的试验。与在黄体期未接受GnRH激动剂的对照组相比, 在黄体期间用GnRH激动剂的患者组中所分析的所有周期显示出更高的植入率, 临床妊娠率和持续妊娠率。因此我们的数据表明, 在黄体期给予GnRH激动剂可以显著增加FET周期中的临床妊娠和持续妊娠率。在FET自然周期中给予GnRH激动剂可显著增加植入率, 临床妊娠率和持续妊娠率。

Keywords:

• GnRH agonist
• luteal phase;frozen–thawed embryo transfer
• FET

Disclosure statement

No potential conflict of interest was reported by the authors.